The FDA now requires earlier MRI screening for Alzheimer’s drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer’s Therapy
Where Today's News Shapes Tomorrow
